Kornimate/medical-research-clean huggingface dataset:
infant crying, a bioacoustic prognostic signal for neurodevelopment

Conditions: Newborn; Vitality; Premature Infants; Infant Development

Summary: crying is a vital communication signal for the baby. product of a complex physiological process, it reflects not only the organization and functioning of the cortical central nervous system and the function of sympathetic and parasympathetic autonomic regulation but also the integrity of three entities: the lungs responsible for ventilatory mechanics and respiratory rhythm, the larynx and its vocal cords as a phonatory organ, and the oropharyngeal tract guaranteeing the resonance of the sound emitted by the vocal cords. crying is usually caused by pain, discomfort, hunger, or separation from parents or other caregivers. crying carries essential information from birth, the expression of which depends closely on the neuroanatomical and functional brain integrity of the child. on a bioacoustic level, crying consists of sequences of complex acoustic signals produced by the vocal folds and filtered by the vocal tract. the vibration frequency of the vocal cords determines the cry's fundamental frequency f0 (and the harmonic frequencies), which is responsible for its more or less low or high pitch. other acoustic cues also characterize each baby's cry.

the objective of the baby's cry 1000/100 study is to evaluate the acoustic characteristics of crying at birth, of term and premature babies and to correlate them with neurodevelopmental outcomes at 2 years of age to see if the bioacoustic characteristics of crying at birth could be predictive of the baby's neurofunctional integrity. to achieve this objective, the investigators wish to document a large bank of recordings of the crying of term or premature babies by relying on deep learning and artificial intelligence approaches, making it possible to process large databases quickly, evaluate the links between acoustics of crying and clinical data at the birth of full-term babies who will benefit from systematic neurodevelopmental monitoring at 2 years (bayley scale).

Eligibility criteria:
inclusion criteria: * for a full-term baby \> 37 weeks * for a premature baby \< 37 weeks * born in the maternity ward of the saint-etienne university hospital * holder of parental authority having received informed information about the study and their right to object * holder of parental authority affiliated to or beneficiary of a social security system * eutrophic between the 10th and 90th percentile on the neonatal curves) exclusion criteria: * refusal of participation by the holder of parental authority * antenatal pathology, nor perinatal asphyxia * holder of minor parental authority * holder of parental authority under curatorship or guardianship * abnormal t1 audiological screening test.

Keywords: newborn crying
analgesic efficacy of transmucosal fentanyl for breakthrough pain caused by interventional gastrostomy

Conditions: Gastrostomy; Breakthrough Pain; Upper Aerodigestive Tract Neoplasms

Summary: patients with head \& neck squamous cell carcinoma often need a gastrostomy. it can be performed with a radiological approach. this procedure is usually not performed under general anesthesia, but local anesthesia is not sufficient to counteract pain due to gastric insufflation and incision of the abdominal wall. standard analgesic treatments are usually not well-fitted due to onset of action or route of administration. an alternative solution could be fentanyl nasal spray, a treatment with a fast onset of action and with easy use allowing repetition if needed, during the procedure. the purpose of this study is to compare analgesic efficacy of nasal instillation of pecfent® to usually administered morphinic analgesic treatment with fast onset of action (oramorph®), in radiologic percutaneous gastrostomy tube placement: * during the procedure * following the procedure (measured by visual analog scale (vas) for pain at 15 min, 30 min, 1 hour, 2 hours, 3 hours, 4 hours, 6 hours and 12 hours after procedure). secondary purposes are to compare easiness of 2 treatments and their adverse effects.


Eligibility criteria:
inclusion criteria: * patient care for cancer of the upper aerodigestive tract (except sinonasal) * \> 18, all weights, all sexes * under balanced background opioid treatment since longer than 7 days (vas \< 5) * needing a radiologic gastrostomy under local anesthesia * informed consent * affiliation to social security plan * preliminary medical examination exclusion criteria: * non balanced morphinic treatment : modification of analgesic treatment during 7 previous days * radiotherapy of nasal fossae/sinus * technical impossibility or contraindication to pecfent®, oramorph® and associated drugs * impossibility of pain evaluation by patient * belonging to protected class: pregnant or breastfeeding woman, person deprived of liberty for judiciary or administrative decision, under-18, person under legal protection or incapable of giving consent, person in life-and-death emergency incapable of giving a preliminary consent
effect of eszopiclone on adherence to cpap and severity of insomnia in patients with comisa

Conditions: Obstructive Sleep Apnea; Insomnia

Summary: the comorbidity between obstructive sleep apnea (osa) and insomnia (comisa) is common, and associated with poorer sleep quality. cpap adherence among comisa patients is worst than among those with osa only. the investigators will compare the effect of eszopiclone 3mg or placebo for 14 days on adherence to cpap after 30 days and after 6 months.

the comorbidity between osa and insomnia (comisa) is common. comisa leads to additive impairment of quality of sleep and quality of life compared to patients with insomnia or osa alone. patients with comisa demonstrate worse adherence to cpap compared to patients with isolated osa. the best therapeutic approach for patients with comisa is still unclear. hypnotics have not been tested among patients with comisa and indication for cpap. the investigators will compare the effect of eszopiclone 3mg or placebo for 14 days on adherence to cpap after 30 days and after 6 months. in addition, the investigators will assess the effect eszopiclone on insomnia severity, quality of life, anxiety.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of insomnia; * moderate or severe osa (ahi ≥ 15 events/h), diagnosed by polysomnography. exclusion criteria: * craniofacial anatomical abnormalities or severe otorhinolaryngological disorders that potentially impair cpap use; * use of hypnotics for more than 7 days in the last 2 months; * renal dysfunction (serum creatinine \>2mg/dl); * severe liver or cardiac dysfunction; * alcoholism; * previous cpap or mandibular advancement device for osa treatment in the last 12 months.

Keywords: comisa obstructive sleep apnea
effect of caudal nalbuphine on postoperative emergence agitation in pediatrics undergoing infra-umbilical surgeries

Conditions: Agitation, Emergence; Post Operative Pain

Summary: effect of caudal nalbuphine on postoperative emergence agitation in pediatrics undergoing infra-umbilical surgeries and pain assessment


Eligibility criteria:
inclusion criteria: * age 2_12 years * both genders * asa i_ii * children undergoing infra-umbilical surgeries exclusion criteria: * guardians refusal * congenital anomalies at the lower spine or meringues * increased intracranial pressure * skin infection at site of injection * bleeding diathesis * known allergy to any drugs used
neonatal cmv-ganciclovir follow-up study

Conditions: Cytomegalovirus Infections

Summary: the purpose of this study is to document the developments associated with puberty and determine if any of the children who previously participated in another research study have been diagnosed with cancer. the previous study was a collaborative antiviral study group (casg) protocol entitled "evaluation of ganciclovir (dhpg) for the treatment of symptomatic congenital cytomegalovirus infections." one of the medications used in this study to treat cytomegalovirus (cmv), ganciclovir, has been known to cause cancer and affect the development of gonads (ovaries in females and testes in males) when administered to animals. children, 9-14 years old, who participated in the previous research study, will participate in this study for 1 day. subjects will be evaluated by an endocrinologist and will have the following procedures performed: a complete physical examination, a single blood sample collected, an x-ray of the left wrist.

ganciclovir has been shown to be carcinogenic, teratogenic, and gonadal toxic in animal models. mice treated with ganciclovir experienced an increase in the incidence of tumors of the preputial gland (males), harderian gland (males), forestomach (males and females), ovaries (females), uterus (females), mammary gland (females), clitoral gland (females), vagina (females), and liver (females). while the preputial and clitoral glands, forestomach, and harderian glands of mice do not have human counterparts, ganciclovir is considered a potential carcinogen in humans. animal data indicate that administration of ganciclovir causes inhibition of spermatogenesis and subsequent infertility, possibly due to inhibition of rapidly dividing cell populations including spermatogonia. in the animal models, these effects were reversible at lower doses and irreversible at higher doses. in both male and female mice, ganciclovir has been shown to cause decreased fertility. gonadal toxicity in rats, mice, and dogs included testicular atrophy in males and, more variable, ovarian atrophy in females. there are no data in humans that demonstrate these effects following treatment with ganciclovir. this study seeks to formally establish the overall sexual development, cancer incidence, and pubertal status of those study subjects who previously received six weeks of ganciclovir as they now approach puberty. the original study was performed from 1986 to 1991, and therefore subjects who were enrolled are now nine to fourteen years of age.

Eligibility criteria:
inclusion criteria: children who received ganciclovir during the earlier study ("evaluation of ganciclovir (dhpg) for the treatment of symptomatic congenital cytomegalovirus infections), and if the parent or legal guardian signs an informed consent and the child signs an assent (where appropriate). exclusion criteria: any individuals not previously enrolled in the casg protocol titled "evaluation of ganciclovir (dhpg) for the treatment of symptomatic congenital cytomegalovirus infections"

Keywords: cmv, cytomegalovirus, children, ganciclovir
does outpatient palliative care improve patient-centered outcomes in parkinson's disease?

Conditions: Parkinson's Disease

Summary: the purpose of this study is to improve outcomes for persons living with parkinson's disease (pd) and their family caregivers. the investigators hypothesize that outpatient interdisciplinary palliative care will improve patient-centered outcomes for pd patients at high-risk for poor outcomes.

palliative care is an approach to caring for individuals with life-threatening illnesses that addresses potential causes of suffering including physical symptoms such as pain, psychiatric symptoms such as depression, psychosocial issues and spiritual needs. palliative care approaches have been successfully applied to improve patient-centered outcomes in cancer as well as several chronic progressive illnesses including heart failure and pulmonary disease. to date there have been minimal attempts to apply these principles to pd although preliminary evidence suggests that pd patients have significant unmet needs under current models of care which may be amenable through a palliative care model. this study will provide critical information to forward this field including data on the comparative effectiveness of outpatient palliative care for pd versus current standards of care; effects of this intervention on cost and service utilization; and the characteristics of patients most likely to benefit from such an approach and the specific services most needed by pd patients and their caregivers.

Eligibility criteria:
inclusion criteria: * fluent in english * uk brain bank criteria for diagnosis of probable pd or multiple systems atrophy (msa) or corticobasal degeneration (cbd) or progressive supranuclear palsy (psp) or lewy body dementia (lbd) * at high risk for poor outcomes as identified by the palliative care needs assessment tool (pc-nat) exclusion criteria: * immediate and urgent palliative care needs * unable or unwilling to commit to study procedures including; 1. randomization, 2. study visits or 3. the addition of a neurologist to their care team * presence of additional chronic medical illnesses which may require palliative services * already receiving palliative care and/or hospice services.

Keywords: palliative care parkinson's disease
implementation of the individual danish emergency process triage

Conditions: Acute Disease; Emergencies; Clinical Syndrome

Summary: the purpose of the study is to implement and evaluate a novel triage algorithm for risk stratification of acutely admitted patients in the emergency department.

triage algorithms are used worldwide to risk assess and prioritize patients in the emergency departments. the aim is to identify patient at risk of deterioration or death and/or with a imminent need of treatment. the triage algorithms are also developed to identify patients at low risk, who safely can be assigned to the waiting room. currently, several different triage algorithms are used, and they are mostly based on consensus and exper- opinion. therefore evidence concerning triage is limited. the investigators has developed a novel evidence-based triage algorithm with integrated individual clinical assesment. the vitals measured at admission assigns the patient to a triage category, and based upon the clinical appearance of the patients, the triage nurse can adjust the assigned triage category to better reflect the patient. the triage algorithm used in denmark is "dept", this algorithm is based purely on vitals and cause of admission and can not be adjusted. i-dept is designed as a cluster randomized stepped-wedge non-inferiority study. the aim is to implement and compare i-dept to the existing triage algorithm. all emergency departments in the capitol region and the region og zealand in denmark will implement i-dept one department at a time (8 centers). the first will start the implementation on october 1, 2020 and after two months the next center will implement i-dept. every two months a new center will start. during 16 months all centers will have implemented i-dept the sequence of centers was determined by randomization. the first 30 days of implementation will be censored and not included in the final analyses. the study will conclude with a period of 30 days follow-up. patients will only be included once.

Eligibility criteria:
inclusion criteria: * admission to a participating emergency department in the study period * full triage assesment in the index admission exclusion criteria: * age below 17 years * death at arrival or before triage assesment

Keywords: triage risk stratification emergency department
a retrospective analysis of neck dissection following complete response to chemoradiation in hnscc

Conditions: Head and Neck Cancer

Summary: rationale: gathering disease-related information from medical charts of patients with primary head and neck cancer who have undergone neck dissection after complete response to chemotherapy and radiation therapy may help doctors learn more about the disease and find better methods of treatment. purpose: this clinical trial is evaluating the medical charts of patients with primary head and neck cancer who have undergone neck dissection after complete response to chemotherapy and radiation therapy.

objectives: * perform a retrospective analysis, by medical chart review, of patients with primary squamous cell carcinoma of the head and neck who underwent neck dissection following complete response to chemoradiotherapy. * determine whether the role of a post-chemoradiotherapy neck dissection affects the outcome of the patient's disease, in terms of overall survival, disease-free survival, and recurrence rates. outline: this is a pilot, retrospective study. patients who have undergone neck dissection after achieving a complete clinical and radiological response to chemoradiotherapy are compared to patients who did not. data are gathered by medical chart review.

Eligibility criteria:
inclusion criteria: * diagnosis of primary squamous cell carcinoma of the head and neck at any of the following sites: * oral cavity * oropharynx * hypopharynx * larynx * complete response achieved after treatment with chemoradiotherapy exclusion criteria: * not specified prior concurrent therapy: * see disease characteristics

Keywords: stage i squamous cell carcinoma of the hypopharynx stage ii squamous cell carcinoma of the hypopharynx stage iii squamous cell carcinoma of the hypopharynx stage iv squamous cell carcinoma of the hypopharynx stage i squamous cell carcinoma of the larynx stage ii squamous cell carcinoma of the larynx stage iii squamous cell carcinoma of the larynx stage iv squamous cell carcinoma of the larynx stage i squamous cell carcinoma of the lip and oral cavity stage ii squamous cell carcinoma of the lip and oral cavity stage iii squamous cell carcinoma of the lip and oral cavity stage iv squamous cell carcinoma of the lip and oral cavity stage i squamous cell carcinoma of the oropharynx stage ii squamous cell carcinoma of the oropharynx stage iii squamous cell carcinoma of the oropharynx stage iv squamous cell carcinoma of the oropharynx stage i verrucous carcinoma of the larynx stage ii verrucous carcinoma of the larynx stage iii verrucous carcinoma of the larynx stage iv verrucous carcinoma of the larynx stage i verrucous carcinoma of the oral cavity stage ii verrucous carcinoma of the oral cavity stage iii verrucous carcinoma of the oral cavity stage iv verrucous carcinoma of the oral cavity
a pilot study comparing nebivolol and atenolol and its effects with exercise in patients with mild to moderate hypertension

Conditions: Hypertension

Summary: the purpose of this study is to determine the effects on exercise capacity of nebivolol compared to atenolol in hypertensive patients.

this was a pilot, phase ii, double-blind, randomized, muticenter, active-comparator, five treatment parallel group dosing and mechanistic study. the study consisted of two phases: 1) screen/washout/single-blind placebo run-in and 2) randomization/treatment. there was a minimum of five scheduled study visits.

Eligibility criteria:
inclusion criteria: * an average sitting diastolic blood pressure (dbp) of greater then or equal to 95 mmhg and less then or equal to 109 mmhg at baseline exclusion criteria: * recent myocardial infarction or stroke * secondary hypertension * contraindications to beta-blocker therapy or stopping prior antihypertensive therapy

Keywords: nebivolol atenolol exercise hypertension
intravenous versus topical administration of low dose epinephrine plus combined administration of intravenous and topical tranexamic acid (txa)for primary total knee arthroplasty

Conditions: Blood Loss

Summary: the purpose of this study is to compare the blood loss of intravenous and topical administration of low dose epinephrine plus combined administration of intravenous and topical tranexamic acid for primary total knee arthroplasty.


Eligibility criteria:
inclusion criteria: * all patients between the ages of 20 and 75 who were diagnosed with osteoarthritis of the knee and scheduled for an elective primary total knee arthroplasty and those who were willing and able to return for follow-up over at least a 6-month postoperative period exclusion criteria: * acute coronary syndrome \< 6 months * glaucoma,pheochromocytoma, thyrotoxicosis, digoxin intoxication, serum potassium \< 3.0 mmol, alcohol abuse, premenopausal women * current treatment with adenosine diphosphate (adp) receptor antagonists, factor xa or thrombin inhibitors,heparin (excluding low molecular weight heparin (lmwh) for perioperative thromboprophylaxis), tricyclic antidepressants, or monoamine oxidase（mao) or catechol-o-methyltransferase (comt) inhibitors * patients with history of thromboembolic disease, bleeding disorder * patients with history of renal impairment, cardiovascular diseases (previous myocardial infarction, atrial fibrillation) or cerebrovascular conditions (previous stroke or peripheral vascular surgery) * allergy to txa

Keywords: arthroplasty, replacement, knee epinephrine tranexamic acid
safety and efficacy of activated recombinant human factor vii in cirrhotic patients undergoing partial hepatectomy

Conditions: Acquired Bleeding Disorder; Cirrhosis

Summary: this trial is conducted in asia. the aim of this trial is to evaluate the haemostatic efficacy of activated recombinant human factor vii in cirrhotic patients scheduled to undergo partial hepatectomy due to liver cancer or benign tumours.


Eligibility criteria:
inclusion criteria: * cirrhosis (child-turcotte score a, b, or c) * scheduled to undergo partial hepatectomy due to liver cancer or benign tumours exclusion criteria: * portal vein thrombosis * clinically documented dvt (deep venous thrombosis) * clinically documented symptoms of severe cardiovascular disease and/or previous myocardial/pulmonary infarction or stroke * present renal insufficiency requiring dialysis
transillumination to reduce post-injection complications in aesthetic medicine

Conditions: E05.642.500

Summary: transillumination (tl) is a noninvasive technique that appears to allow preliminary detection of superficial vascular structures of the face to avoid intravascular ha injection. the purpose of our study was to test the efficacy of tl in terms of its sensitivity to locate vessels in the areas undergoing treatment and to reduce post-injection vascular complications.

transillumination was used during the injection of hyaluronic acid to reduce the risk of intravascular injection. for the purpose of randomization, patients were asked to choose a sealed envelope. inside the envelope was a piece of paper indicating on which side of the face (right or left) the transillumination would be used. for each filler injection, transillumination was used on one side; on the other side of the face, the injection was administered without the use of any vascular exploration method. after the vessels had been located on the side chosen for the transillumination technique, a skin-marker pencil was used to draw the vascular mapping of the upper part of the face, which in our opinion represented the area most at risk of complications, the middle and the lower parts of the face. then ice was applied on both sides of the face for 15 s before to proceed with the injections in order to cause vasoconstriction and to further decrease the risk of an intravascular injection.transillumination sensitivity for locating the vessels of the face was assessed.

Eligibility criteria:
inclusion criteria: * patients presenting for facial injections of hyaluronic acid exclusion criteria: * patients with a history of allergy to a component of hyaluronic acid * patients with arteritis (horton) * patients who have had previous facial surgery * pregnant or nursing patients

Keywords: transillumination aesthetic injection asthetic post-injection complications hyaluronic acid facial injection